UroGen Pharma Ltd. (URGN)
33.48
-0.27
(-0.80%)
USD |
NASDAQ |
Oct 29, 16:00
33.15
-0.33
(-0.99%)
After-Hours: 20:00
UroGen Pharma Enterprise Value : 1.723B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 1.723B |
| October 28, 2026 | 1.736B |
| October 27, 2026 | 1.744B |
| October 26, 2026 | 1.750B |
| October 23, 2026 | 1.772B |
| October 22, 2026 | 1.805B |
| October 21, 2026 | 1.821B |
| October 20, 2026 | 1.798B |
| October 19, 2026 | 1.756B |
| October 16, 2026 | 1.776B |
| October 15, 2026 | 1.876B |
| October 14, 2026 | 1.874B |
| October 13, 2026 | 1.957B |
| October 12, 2026 | 1.958B |
| October 09, 2026 | 1.887B |
| October 08, 2026 | 1.894B |
| October 07, 2026 | 2.076B |
| October 06, 2026 | 2.111B |
| October 05, 2026 | 2.177B |
| October 02, 2026 | 2.110B |
| October 01, 2026 | 2.068B |
| September 30, 2026 | 2.072B |
| September 29, 2026 | 2.064B |
| September 28, 2026 | 2.086B |
| September 25, 2026 | 2.108B |
| Date | Value |
|---|---|
| September 24, 2026 | 2.102B |
| September 23, 2026 | 2.121B |
| September 22, 2026 | 2.176B |
| September 21, 2026 | 2.198B |
| September 18, 2026 | 2.200B |
| September 17, 2026 | 2.235B |
| September 16, 2026 | 2.212B |
| September 15, 2026 | 2.127B |
| September 14, 2026 | 2.171B |
| September 11, 2026 | 2.154B |
| September 10, 2026 | 2.151B |
| September 09, 2026 | 2.286B |
| September 08, 2026 | 2.228B |
| September 04, 2026 | 2.241B |
| September 03, 2026 | 2.280B |
| September 02, 2026 | 2.258B |
| September 01, 2026 | 2.207B |
| August 31, 2026 | 2.193B |
| August 28, 2026 | 2.219B |
| August 27, 2026 | 2.310B |
| August 26, 2026 | 2.332B |
| August 25, 2026 | 2.352B |
| August 24, 2026 | 2.343B |
| August 21, 2026 | 2.377B |
| August 20, 2026 | 2.374B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 1.885B |
| MeiraGTx Holdings Plc | 883.46M |
| Insmed, Inc. | 24.08B |
| Ironwood Pharmaceuticals, Inc. | 915.91M |
| Viking Therapeutics, Inc. | 2.720B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.35M |
| Revenue (Quarterly) | 72.46M |
| Total Expenses (Quarterly) | 86.81M |
| EPS Diluted (Quarterly) | -0.2848 |
| Gross Profit Margin (Quarterly) | 90.93% |
| Profit Margin (Quarterly) | -19.81% |
| Earnings Yield | -5.96% |
| Normalized Earnings Yield | -5.955 |